Identity
- Security key
- 11492
- Ticker
- AIM
- Type
- CS — Common Stock
- Exchange
- NYSE American, LLC(XASE)
- Venue group
- NYSE
- Operating MIC
- XNYS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 1995-11-02
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- AIM
Detail
Enriched 2026-08-14 20:47
- Market cap
- $7,125,130.97
- Shares outstanding (class)
- 27,724,245
- Shares outstanding (weighted)
- 27,724,245
- SIC
- 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Employees
- 21
- Location
- OCALA, FL
- Homepage
- https://www.aimimmuno.com
- Description
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Market cap and share counts drift.